Bristol-Myers Squibb Company Ce
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$0.09
FAIR PRICE
$0.06
MARGIN
$0.03
NOW AVAILABLE
Get notified when CELG-RI's fair price changes
Push notifications when CELG-RI's valuation shifts. Available on iOS and Android.
FPI RATING
High-quality fundamentals and attractive valuation across the board.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$0.05
Fair price × 0.80
DISTANCE
46.7%
Price to entry level
At the current price of $0.09, CELG-RI trades 46.7% above the conservative entry level of $0.05. This entry level represents a 20% margin of safety below the calculated fair price of $0.06 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
P/E RATIO HISTORY
Loading chart data...
METHODOLOGY
How we calculate CELG-RI's fair price
Bristol-Myers Squibb Company Ce's fair price of $0.06 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $0.09, CELG-RI trades 33.3% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting CELG-RI's risk profile.
RELATIVE · 30%
Comparing CELG-RI's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for CELG-RI, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate CELG-RI's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for CELG-RI.
Explore on BuliosFAQ
What is the fair price of CELG-RI?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Bristol-Myers Squibb Company Ce is $0.06. At the current market price of $0.09, CELG-RI trades 33.3% above its calculated fair value.
Is CELG-RI overvalued or undervalued?+
Bristol-Myers Squibb Company Ce is currently overvalued based on our valuation model. The stock trades at $0.09, which is 33.3% above the fair price of $0.06. The P/E ratio of 0.0x is a key metric in the valuation.
What is the margin of safety for CELG-RI?+
With a 20% margin of safety applied to the fair price of $0.06, the conservative entry level for CELG-RI is $0.05. At the current market price of $0.09, the stock trades 46.7% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is CELG-RI's fair price updated?+
We update fair price calculations for CELG-RI daily after market close. The current fair price of $0.06 incorporates the latest market data and sector multiples.
What factors affect CELG-RI's fair price calculation?+
CELG-RI's fair price of $0.06 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 0.0x, ROE of 25.8%.
Is CELG-RI a good buy right now?+
At $0.09, CELG-RI trades 33.3% above our fair value estimate of $0.06. The stock is currently overvalued. ROE stands at 25.8% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does CELG-RI pay dividends?+
CELG-RI does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.